Immunotherapy dosing showdown: higher doses may mean more side effects
NCT ID NCT07174453
First seen Oct 31, 2025 · Last updated May 21, 2026 · Updated 30 times
Summary
This study is for adults with solid tumors who are eligible for pembrolizumab or nivolumab. It compares higher doses (every 4-6 weeks) to lower doses (every 2-3 weeks) to see which causes fewer severe immune-related side effects. The goal is to find the safest dosing schedule without compromising treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The University of Kansas Cancer Center
RECRUITINGWestwood, Kansas, 66205, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.